

Gale Group PharmaBiomed Business Journals

Date revised: 2 August 2021

Description

The Gale Group PharmaBiomed Business Journals database provides international coverage of full-text articles from trade journals on pharmaceuticals, biotechnology and healthcare. The database is an excellent source of information on methods and techniques, business practices, new products, companies, markets, market share, research and development, regulations and applied technologies in these fields.

Date Coverage

1990–present

Geographic Coverage

International

Subject Coverage

Use this database to answer questions like:

- What is the market for medical instruments in Germany?
- What new products in anti-infectives are being developed?
- What are the current trends in transplants?
- What are the major genetic engineering companies in Australia?

Update Frequency

Daily

Document Types

Journal Articles

Publisher

Gale Group PharmaBiomed Business Journals is provided by Gale, a part of Cengage Learning. Questions concerning Electronic Search Assistance should be directed to:

Gale, a part of Cengage Learning
27500 Drake Road
Farmington Hills, MI 48331-3535
USA

In addition to [Search Fields](#), other tools available for searching are: [Limit Options](#), [Browse Fields](#), [“Narrow Results By” Limiters](#) and [Look Up Citation](#). Each is listed separately below. Some data can be searched using more than one tool.

Sample document



Full text < Back to results

< Previous Document 12 of 105

Add to selected items

Save to My Research

Email

Print

Cite

Export

TI
PUB

Secukinumab shows superiority to etanercept

Petrou, Ilya. **Dermatology Times** 35.1 (Jan 2014): 22(2).

[Show duplicate items from other databases](#)

TX

Full Text [Translate](#)

ISTANBUL - Recent head-to-head clinical trial results involving secukinumab (Novartis) and etanercept (Amgen) show that secukinumab appears to be significantly superior in the treatment and management of patients with moderate-to-severe plaque psoriasis, perhaps heralding a new standard of care for this patient population.

Novartis recently announced the new data from the phase 3 FIXTURE study, which compared the safety and efficacy of secukinumab (an interleukin-17A inhibitor) and etanercept (a tumor necrosis factor inhibitor) using two dosing regimens in patients with plaque psoriasis, at the 22nd Congress of the European Association of Dermatology and Venereology (EADV) in Istanbul.

The randomized, double-blind, placebo-controlled, 52-week multicenter study included 1,036 patients, and compared two doses of secukinumab (300 mg and 150 mg) with etanercept 50 mg and placebo. The co-primary endpoints were assessed at week 12 and compared secukinumab efficacy versus placebo according to the Psoriasis Area and Severity Index 75 (PASI 75), and the Investigator's Global Assessment.

The clinical trial met all primary and pre-specified key secondary endpoints. Both doses of secukinumab demonstrated improved efficacy to etanercept throughout the study and results showed that secukinumab patients' skin cleared faster and longer than etanercept patients, beginning as early as week two. Importantly, the data also showed that twice as many secukinumab patients experienced almost clear skin (PASI 90) and completely clear skin (PASI 100) by week 12, compared to patients on etanercept.

(. . .)

Patients with plaque psoriasis will often also have psoriatic arthritis and, Dr. Lebwohl says, the tumor necrosis factor (TNF) blockers such as etanercept and adalimumab have a proven track record in the treatment and management of patients with psoriatic arthritis.

"Both of these TNF blockers have been shown to prevent the X-ray progression of joint disease, which is very important in our psoriasis patients who have concomitant psoriatic arthritis. This is another important factor that will also impact our decision on what drug to use in our patients," Dr. Lebwohl says. "Nevertheless, it must be said that secukinumab looks really good right now, as it has shown to work very quickly with a high efficacy, and can achieve remissions that are long-lasting."

QUICK READ

Recent trial data shows secukinumab to be a superior therapy, possibly representing a new standard of care in patients with moderate to severe plaque psoriasis.

Disclosures: Dr. Lebwohl is a consultant and investigator for Amgen and Novartis.

Ilya Petrou, M.D. | Senior Staff Correspondent

Word count: **822**

Copyright 2014 Gale, Cengage Learning. All rights reserved.

Indexing (details) Cite

BDE,SU

Business subject Etanercept;
Pharmaceutical industry;
Psoriasis;
Tumor necrosis factor

LOC,SU

Location Switzerland

CO

Company / organization Novartis AG

IF,SU

Identifier (keyword) Trade, NVTSY

NAICS,CC

NAICS classification 325411: Medicinal and Botanical Manufacturing

PRCC,CC

Product classification 2834000: Pharmaceutical Preparations

SIC,CC

SIC classification 2833: Medicinals and botanicals;

2834: Pharmaceutical preparations

TI	Title	Secukinumab shows superiority to etanercept
AU,FAU	Author	Petrou, Ilya
PUB	Publication title	Dermatology Times
VO	Volume	35
ISS	Issue	1
PG	Pagination	22(2)
PD,YR	Publication date	Jan 2014
PUB	Publisher	Advanstar Communications, Inc.
JSU	Journal subject	Business, Health care industry, Pharmaceuticals and cosmetics industries
ISSN	ISSN	0196-6197
JC	Journal code	OUMR
PSTYPE	Source type	Magazine/Journal
LA	Language of publication	English
DTYPE	Document type	Magazine/Journal
	Source attribution	Gale PharmaBiomed Business Journals, © Publisher specific
AN	Accession number	359173074
	Document URL	http://search.proquest.com/professional/docview/1500917163?accountid=137296
	Copyright	Copyright 2014 Gale, Cengage Learning. All rights reserved. COPYRIGHT 2014 Advanstar Communications, Inc.
DCRE	Date created	2014-02-21
UD	Updates	2014-02-22
FAV	First available	2014-02-22
	Database	Gale Group PharmaBiomed Business Journals (1990 - current)

Search fields

Field Name	Field Code	Example	Description and Notes
Abstract	AB	ab("optimized reading zone")	Most articles do not have abstracts, but all documents have full text.
Abstract present	ABANY	"optimized reading zone" AND abany(yes)	Add: <i>AND ABANY(YES)</i> to a query to limit retrieval to records with abstracts.
Accession number	AN	an(359173074)	A unique document identification number assigned by Gale.
Advertising classification	ADC	adc(57: new products/services)	Also searchable using CC.
All fields (except full text)	ALL	all("plaque psoriasis")	Searches all fields except the full text in full text files.
All fields + full text	--	"plaque psoriasis"	Searches all fields including the full text in full text files.
Author Author First Name Author Last Name	AU AUFN AULN	au(petrou, ilya) aufn(ilya) auln(petrou)	Includes all Authors.
First author	FAU	fau("duber-smith, Darrin")	First name listed in Author field.
Business subjects	BDE	bde("pharmaceutical industry")	
Classification	CC	cc("pharmaceutical preparations") cc(2834*)	Searches SIC, NAICS, Event & Product classifications.
Company/organization ¹	CO,COM	co(Novartis ag)	
Date created	DCRE	dcre(2014-02-21)	
Document text	TX	tx("psoriatic arthritis")	
Document title Alternate title	TI OTI	ti("Secukinumab shows superiority to etanercept") oti(affordable care act)	Includes Title, Alternate Title, Original Title, and Subtitle but not Publication Title (PUB). Includes both alternate and original language of document title, if available. Field code TI also searches the Alternate title.
Title only	TIO	tio(affordable care act)	Searches only the Title, not subtitle or alternate title.

¹ A Lookup/Browse feature is available for this field in the Advanced Search dropdown or in Browse Fields.

Field Name	Field Code	Example	Description and Notes
Document type	DTYPE	dtype(article) dtype(review)	
Event classifications ¹	EVT	evt(336: product introduction)	Displays in Classification and in Event classification. Also searchable using CC.
First available	FAV	fav(2014-02-22)	Indicates the first time a document was loaded in a specific database on PQD. It will not change regardless of the number of times the record is subsequently reloaded, as long as the accession number does not change.
From database ²	FDB	IL-17A AND fdb(1008284) IL-17A AND fdb(pharmabiomedbusiness)	Useful in multi-file searches to isolate records from a single file. FDB cannot be searched on its own; specify at least one search term then AND it with FDB.
Identifier (Keyword)	IF	if(trade)	Included in SU search.
ISSN	ISSN	issn(0196-6197)	
Journal code	JC	jc(0UMR)	
Journal subject	JSU	jsu(health care industry)	
Location ¹	LOC	loc(switzerland)	
NAICS ¹	NAICS	naics(325411: medicinal and botanical manufacturing)	Displays in Classification and in NAICS code. Also searchable using CC.
Person ¹	PER	per(jones, stephen)	
Product classification code ¹	PRCC	prcc("pharmaceutical preparations") prcc(2834000)	Displays in Classification and in Product classification. Also searchable using CC.
Publication date	PD	pd(201401)	Date range operators are supported.
Publication title ¹	PUB	pub(dermatology times)	
Publication year	YR	yr(2014) yr(>2009)	Date range operators are supported.
Publisher	PB	pb(advanstar communications)	
Source information	SRC	src(2013) src(chemist)	Searches various source fields including PUB, VOL and ISSN.
Source type	PSTYPE	pstype(magazine)	
Subject	SU	su(tumor necrosis factor)	Searches Identifiers and Company as subject. Company retrieval will not display in Subject.
Updated	UD	ud(2014-02-22)	The date(s) the record was loaded as a result of an update provided by the supplier.
US SIC code	SIC	sic(2833) sic("medicinals and botanicals")	Displays in Classification and in Subject. Also searchable using CC.
Volume	VO	vo(39)	

Limit options

Limit options are quick and easy ways of searching certain common concepts. Check boxes are available for:

Full text

A short list of choices is available for:

Document type

Date limiters are available in which you can select single dates or ranges for date of **publication** and **updated**.

² Click the "Field codes" hyperlink at the top right of the Advanced Search page. Click "Search syntax and field codes", then click on "FDB command" to get a list of database names and codes that can be searched with FDB.

Browse fields

You can browse the contents of certain fields by using Look Up lists. These are particularly useful to validate spellings or the presence of specific data. Terms found in the course of browsing may be selected and automatically added to the Advanced Search form. Look Up lists are available in the fields drop-down and in the search options for:

Company/organization, Person, Location

and in the fields drop-down only for:

Publication, Event classification, NAICS codes, Product classification, SIC codes

“Narrow Results by” limiters

When results of a search are presented, the results display is accompanied by a list of “Narrow results by” options shown on the right panel. Click on any of these options and you will see a ranked list showing the most frequently occurring terms in your results. Click on the term to apply it to (“narrow”) your search results. “Narrow results by” limiters in Gale Group PharmaBiomed Business Journals include:

Full text, Source type, Publication title, Document type, Subject, NAICS Code, Product Classification, SIC Code, Company/organization, Location, Person, Language and Publication date

Look up citation

If you need to trace a particular bibliographic reference, use the Look Up Citation feature. Find a link to this toward the top left of the Advanced Search page, or in the drop list under Advanced on any search form; click this and you will go to a form where you can enter any known details of the citation, including:

Document title, Author, Publication title, ISSN, ISBN, Volume, Issue, Page, Date, DOI

Terms & Conditions

These Databases (the "Databases") are copyrighted by Gale, a part of Cengage Learning. The Gale Databases are provided "as is" without warranty of any kind. Neither Gale, a part of Cengage Learning, nor any of its data suppliers make any warranty whatsoever as to the accuracy or completeness of any of the Databases or the results to be obtained from using the information contained therein and neither Gale, a part of Cengage Learning, nor any of its data suppliers shall be responsible for any claims attributable to errors, omissions or other inaccuracies in the information contained in any Gale Databases. The entire risk as to the results and performance of any Gale Database is assumed by the user of that Database. Further, neither Gale, a part of Cengage Learning, nor any of its data suppliers make any representations or warranties either express or implied, with respect to any of the Databases, including, but not limited to, the quality, performance, merchantability or fitness for a particular purpose of any Gale Database or any information contained therein. In no event shall Gale, a part of Cengage Learning, or any of its data suppliers be liable for direct, indirect, special, incidental or consequential damages arising out of the use of or inability to use any Gale Database or for any loss or damage of any nature caused to any person as a result of the use of the Database. Material contained in any Database may not be sold. Material contained in any Database may not be made available in any manner whatsoever to a third party or duplicated, redistributed or archived except solely for the customer's own internal use and according only to (1) the Terms & Conditions in Dialog's Service Agreement and (2) the terms and conditions contained below.

A user may not:

- Redistribute, copy or electronically store (archive) all or a majority of records from a single issue of a publication retrieved from the Databases.
- Electronically store (archive) in machine-readable form for more than twelve (12) months records.
- Delete or remove from a record or data the copyright credits or the name of the Database from which such record or data was retrieved.
- Republish, distribute or make available in any manner whatsoever to third parties who are not part of the user's organization records or data retrieved from the Databases.
- Use any records or data to create a derivative work except for a compilation of electronically stored data for internal use only.

Notwithstanding the above restrictions, a bona fide information broker may make and provide one copy of search results obtained from the Databases to a single customer outside that information broker's organization provided that such information broker notifies such single customer that the information is copyrighted material which can be used for internal purposes only and cannot be copied, sold or republished.

IF THERE IS A CONFLICT BETWEEN THESE TERMS AND CONDITIONS AND DIALOG'S CUSTOMER SUBSCRIPTION AGREEMENT, THE ABOVE TERMS AND CONDITIONS SHALL GOVERN. ANY OTHER USE OF THE DATABASES WITHOUT EXPRESS WRITTEN PERMISSION IS STRICTLY PROHIBITED.

The material contained in Gale Group PharmaBiomed Business Journals is provided only for informational purposes and should not be construed as medical advice or instruction. Consult your health professional for advice relating to a medical problem or condition.

[Dialog Standard Terms & Conditions](#) apply.

Contact Global Customer Support

Email: Customer@dialog.com

Within North America **1 800 3 DIALOG (1 800 334 2564)**

Outside North America **00 800 33 DIALOG (00 800 33 34 2564)**